Special Issues

Special Issue Title: Endometrial Cancer

· Print Special Issue Flyer

· Deadline for manuscript submissions:  30 October 2021


Special Issue Editor

Guest Editor

Fabio Landoni, MD, PhD

Gynecologic Oncology University of Milan and Bicocca S. Gerardo Hospital, Monza, Italy

Website | E-Mail

Interests: Laparoscopic Surgery; Surgery; Oncology; Gynaecological Surgery; Gynecologic Oncology; Hysterectomy; Cancer Prevention; Pelvic Reconstructive Surgery; Gynecologic Surgical Procedures; Ovarian Cancer; Endometrial Cancer; Ovarian Neoplasms; Uterine Neoplasms; Pelvic Neoplasms; Vulvar Diseases


Torres Lobaton, MD

Professor of Gynecology Oncology, Hospital General de Mexico, Mexico City, Mexico

Website | E-Mail

Interests: Oncological Gynecology; Oncologist Surgeon


Special Issue Information

1) Pathology of endometrial carcinoma: up-to-date integrated morpho-immunohistochemical and  molecular classification

2) Evidence based surgery (mini-invasive vs laparotomy, sentinel nodes dissection vs  lymphadenectomy, fertility sparing surgery)

3) Adjuvant treatment: when and which one

4) Follow-up: Minimalist versus intensive

5) Living after cancer is not surviving to cancer: improving quality of life


Fabio Landoni, MD, PhD and Torres Lobaton, MD

Guest Editors

 

Manuscript Submission Information

Manuscripts should be submitted online at https://ejgo.imrpress.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a double-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. European Journal of Gynaecological Oncology is an international peer-reviewed open access quarterly journal published by IMR Press.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is $1250.  Submitted papers should be well formatted and use good English.


Keywords

Endometrial Cancer; Medical Treatment; Risk Factors


Share This Special Issue

     


Planned Papers

Type: Review
Title: Current Histologic and Molecular Classifiers of Endometrial Cancer
Authors: Mahmoud A. Khalifa, MD, PhD; Boris Winterhoff, MD; Britt Erickson, MD; Molly Klein, MD University of Minnesota


Please wait a minute...
For Selected: Toggle Thumbnails
Concurrent immunohistochemical testing of L1CAM and MMR proteins adds value in risk stratification of endometrial cancer: a proof of concept
Jaswinder Chalia, Musse Hussein, Mariya Farooqui, Jordan Mattson, Sally A. Mullany, Molly E. Klein, Boris Winterhoff, Mahmoud A. Khalifa
European Journal of Gynaecological Oncology    2021, 42 (5): 887-892.   DOI: 10.31083/j.ejgo4205135
Abstract80)   HTML6)    PDF(pc) (1377KB)(43)       Save

Objectives: Histologic classification along with clinical stage predominantly drive management of patients with endometrial cancer. However, current clinico-pathologic risk-based stratification has proven suboptimal, inciting efforts to identify additional molecular classifiers, such as L1CAM. This is of particular relevance for the TCGA-defined Nonspecific Molecular Profile (NSMP) and MMR-deficient (MMR-d) groups of tumors, both of which are classified as having an intermediate prognosis. In current practice, L1CAM immunostaining is reserved for NSMP tumors that have been classified as MMR-proficient. The aim of this study is to investigate L1CAM testing in tandem, rather than sequential with that of MMR. Methods: A total of 149 MMR-tested endometrial carcinoma cases from 2019–2020 were identified, of which, 45 had also undergone L1CAM immunostaining. Clinical information including grade, stage, and treatment was reviewed. This was correlated with percentage of L1CAM positivity and MMR-status. Results: L1CAM positivity was noted in 7/45 (15.6%) cases with 6/45 (13.3%) additional cases demonstrating only focal positivity. MMR deficiency was noted in 24/45 (53.3%) of the cases in which L1CAM was performed. Of the cases that showed L1CAM positivity, 6/7 (85.7%), were found to be MMR-deficient. Within the remaining group in which L1CAM was not performed, 24/104 (23.1%) of cases showed MMR deficiency. Conclusions: Current findings suggest that L1CAM positivity is not mutually exclusive when correlating with MMR status. Performing L1CAM immunostaining on all endometrial carcinomas may assist in appropriate treatment for patients with L1CAM positivity, and in particular, in MMR-proficient cases classified within the NSMP category.
Related Articles | Metrics

Current Issue

  • Volume 42, Issue 5